In one aspect, the present disclosure provides a use of rifabutin and a second antibiotic selected from the group consisting of a polymyxin and cefiderocol in the manufacture of a medicament for combination therapy to treat an *A. baumannii* infection in a subject, wherein the rifabutin and second antibiotic are the only antibiotics in the medicament. In another aspect, the present disclosure provides a use of rifabutin in the manufacture of a first medicament and use of a second antibiotic selected from the group consisting of a polymyxin and cefiderocol in the manufacture of a second medicament, wherein the first and second medicaments are to be used in combination therapy to treat an *A. baumannii* infection in a subject, and wherein the rifabutin and second antibiotic are the only antibiotics in the medicament. In yet another aspect, the present disclosure provides a use of rifabutin in the manufacture of a medicament for use in combinatorial therapy for treating an *A. baumannii* infection in a subject, wherein said medicament is to be administered in combination with a second antibiotic selected from the group consisting of a polymyxin and cefiderocol, and wherein the rifabutin and second antibiotic are the only antibiotics in the medicament.

In an example, the disclosure provides methods of treating an *A. baumannii* infection in a subject by providing to a subject infected with *A. baumannii* rifabutin and a second antibiotic.

Claims

What is claimed is:

1. Use of rifabutin and a second antibiotic selected from the group consisting of a polymyxin and cefiderocol in the manufacture of a medicament for combination therapy to treat an *A. baumannii* infection in a subject, wherein the rifabutin and second antibiotic are the only antibiotics in the medicament.

2. Use of rifabutin in the manufacture of a first medicament and use of a second antibiotic selected from the group consisting of a polymyxin and cefiderocol in the manufacture of a second medicament, wherein the first and second medicaments are to be used in combination therapy to treat an *A. baumannii* infection in a subject, and wherein the rifabutin and second antibiotic are the only antibiotics in the medicament.

3. Use of rifabutin in the manufacture of a medicament for use in combinatorial therapy for treating an *A. baumannii* infection in a subject, wherein said medicament is to be administered in combination with a second antibiotic selected from the group consisting of a polymyxin and cefiderocol, and wherein the rifabutin and second antibiotic are the only antibiotics in the medicament.

4. The use of any one of claims 1-3, wherein the polymyxin is polymyxin B.

5. The use of any one of claims 1-3, wherein the polymyxin is colistin.

6. The use of any one of claims 1-3, wherein the second antibiotic is cefiderocol.

7. The use of any one of claims 1-3, wherein the rifabutin is to be administered intravenously.

8. The use of any one of claims 1-3, wherein the rifabutin is to be administered by inhalation.

9. The use of any one of claims 1-3, wherein the rifabutin is to be administered orally.

10. The use of any one of claims 1-3, wherein the rifabutin and the second antibiotic are to be provided in a single formulation.

11. The use of any one of claims 1-3, wherein the rifabutin and the second antibiotic are to be provided separately.

12. The use of any one of claims 1-3, wherein the *A. baumannii* comprises a rpoB mutation.